Clinical Trial Update: A Clinical Study of Dual-Target, Universal CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus [Phase 1]

View source ↗

Summary

Phase 1 study update indicates Hangzhou Qihan Biotech is actively recruiting participants for a dual-target universal CAR-T cell therapy for refractory systemic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Dual-Target Universal CAR-T Cell Therapy

Snippet

Sponsor: Hangzhou Qihan Biotech Co., Ltd. | Conditions: Systemic Lupus Erythematosus (SLE) | Phase 1 | Status: RECRUITING